Shots:

• The NMPA has approved Byvasda for the treatment of patients with NSCLC and metastatic colorectal cancer. The approval follows TYVYT (sintilimab injection) approval- indicated to treat patients with Hodgkin's lymphoma- granted in Dec’2018
• The launch of Byvasda will provide Chinese patients with high-quality and relatively more affordable bevacizumab biosimilar injection
• In Jan’2020- Innovent granted commercial rights of Byvasda to in the US and Canada to Coherus BioSciences. Byvasda is a recombinant humanized anti-VEGF mAb targeting VEGF receptors on the surface of vascular endothelial cells- thus inhibiting signaling pathways such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK

Click here to read full press release/ article 

Ref: Buinesswire | Image: Innovent